Skip to main content
Erschienen in: Reactions Weekly 1/2016

01.11.2016 | Case report

Metformin

Gastrointestinal side-effect: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Jayasinghe KNU, et al. Combining SGLT2 inhibitor and GLP-1 agonist: Exaggerated weight loss in a morbidly obese patient with type 2 diabetes. British Journal of Diabetes and Vascular Disease 16: 138-139, No. 3, Jul-Sep 2016. Available from: URL: http://doi.org/10.15277/bjd.2016.092 - United KingdomCrossRef Jayasinghe KNU, et al. Combining SGLT2 inhibitor and GLP-1 agonist: Exaggerated weight loss in a morbidly obese patient with type 2 diabetes. British Journal of Diabetes and Vascular Disease 16: 138-139, No. 3, Jul-Sep 2016. Available from: URL: http://​doi.​org/​10.​15277/​bjd.​2016.​092 - United KingdomCrossRef
Metadaten
Titel
Metformin
Gastrointestinal side-effect: case report
Publikationsdatum
01.11.2016
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2016
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-016-22846-8

Weitere Artikel der Ausgabe 1/2016

Reactions Weekly 1/2016 Zur Ausgabe

Case report

Acenocoumarol

Case report

Multiple drugs

Case report

Rifampicin

Case report

Apixaban

Case report

Mitomycin